Search Within

Anas Younes

Formats
  1. Meeting Abstract (153)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (320)
  2. Department of Medicine (320)
  3. Executive Committee, Center for Hematologic Malignancies (320)
  4. Hematologic Malignancies, Division of (320)
  5. Lymphoma (320)
  6. Epidemiology and Biostatistics (82)

More Groups

People
  1. Andrew Zelenetz (89)
  2. Connie Batlevi (81)
  3. David Straus (74)
  4. Matthew Matasar (68)
  5. Anita Kumar (67)
  6. Paul Hamlin (67)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (91)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (320)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BET inhibition-induced GSK3β feedback enhances lymphoma vulnerability to PI3K inhibitors
    Journal Article

    Derenzini, E.; Mondello, P.; Erazo, T.; Portelinha, A.; Liu, Y.; Scallion, M.; Asgari, Z.; Philip, J.; Hilden, P.; Valli, D.; more...
    Cell Reports (2018)

    Fulltext@MSK | Save
  • Report of the 14th International Conference on Malignant Lymphoma (ICML) closed workshop on future design of clinical trials in lymphomas
    Journal Article

    Stathis, A.; Iasonos, A.; Seymour, J. F.; Thieblemont, C.; Ribrag, V.; Zucca, E.; Younes, A.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
    Journal Article

    Romaguera, J. E.; Wang, M.; Feng, L.; Fayad, L. E.; Hagemeister, F.; McLaughlin, P.; Rodriguez, M. A.; Fanale, M.; Orlowski, R.; Kwak, L. W.; more...
    Cancer (2018)

    Fulltext@MSK | Save
  • Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay
    Journal Article

    Intlekofer, A. M.; Joffe, E.; Batlevi, C. L.; Hilden, P.; He, J.; Seshan, V. E.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, C. H.; Portlock, C.; more...
    Blood Cancer Journal (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin Lymphoma from the phase 2 CheckMate 205 study
    Meeting Abstract

    Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G. P.; Fanale, M. A.; Armand, P.; more...
    British Journal of Haematology (2018)

    Fulltext@MSK | Save
  • Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm phase II CheckMate 205 trial
    Journal Article

    Armand, P.; Engert, A.; Younes, A.; Fanale, M.; Santoro, A.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; Cohen, J. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma
    Journal Article

    Roemer, M. G. M.; Redd, R. A.; Cader, F. Z.; Pak, C. J.; Abdelrahman, S.; Ouyang, J.; Sasse, S.; Younes, A.; Fanale, M.; Santoro, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
    Meeting Abstract

    Blum, K. A.; Abramson, J.; Maris, M.; Flinn, I.; Goy, A.; Mertz, J.; Sims, R.; Garner, F.; Senderowicz, A.; Younes, A.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma
    Journal Article

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illés, Á.; Picardi, M.; more...
    New England Journal of Medicine (2018)

    Fulltext@MSK | Save